SAN FRANCISCO, Sept. 11, 2012 (GLOBE NEWSWIRE) -- ICAAC 2012 -- Trius Therapeutics, Inc. (Nasdaq:TSRX), a biopharmaceutical company focused on the discovery, development and commercialization of innovative antibiotics for life-threatening infections, announced today that several abstracts related to tedizolid phosphate (TR-701) are being presented at the 52 nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) meeting in San Francisco from September 9 to September 12, 2012. A total of 12 tedizolid-related posters have been accepted for presentation, including clinical results and preclinical studies of tedizolid against gram-positive bacterial infections.
Trius Therapeutics Announces Data Presentations On Tedizolid At 52nd Annual ICAAC Meeting
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
More than 30 investing pros with skin in the game give you actionable insight and investment ideas.